search

Theravance Biopharma Inc (TBPH)

OverviewChartFinancialsStatisticsEarningsInsider transactionsETFsNews

News

Real-time news feed aggregating press releases, regulatory filings, and global media coverage for a single company, filterable by date range, relevance score, and sentiment classification. Each article is tagged with company-specific and overall market sentiment — allowing investors to separate fundamental catalysts from broader market noise and monitor how the narrative around a stock is evolving over time.

Relevance *
40
Theravance Biopharma Shareholders Endorse Merger with Zymeworks Inc.
Sep 19, 2026

Theravance Biopharma Shareholders Endorse Merger with Zymeworks Inc.

Theravance Biopharma shareholders have approved the merger agreement with Zymeworks Inc. during an extraordinary general meeting on September 18, 2026. The Merger Proposal received overwhelming support, satisfying the supermajority condition required for closing. The merger is now anticipated to be completed on or about September 23, 2026, subject to the fulfillment of remaining conditions.
Company relevance
100.00%
Company sentiment
Bullish
Overall sentiment
Bullish
Theravance Biopharma SVP Farnum Rhonda Sells 13,314 Shares at $17.03 Each
Sep 18, 2026

Theravance Biopharma SVP Farnum Rhonda Sells 13,314 Shares at $17.03 Each

Farnum Rhonda, SVP of Communications and Medical Affairs at Theravance Biopharma, sold a total of 13,314 shares at $17.03 each across three transactions on September 15, 2026. This sale reduced her holdings by approximately 5.9%, leaving her with 213,476 shares after the transactions. The disposals were all recorded under code S.
Company relevance
100.00%
Company sentiment
Somewhat-Bearish
Overall sentiment
Somewhat-Bearish